Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

(2022) E. Van Cutsem et al.   BRITISH JOURNAL OF CANCER

Colorectal Cancer Surveillance With Circulating Tumor DNA Assay

(2022) Alan P. Venook   JAMA Network Open

Metastatic Lung Tumors from Colorectal Cancer with <i>EGFR</i> Mutations That Responded to Osimertinib

(2022) Atsushi Yanagisawa et al.   INTERNAL MEDICINE

Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer

(2021) Jun Gong et al.   Cancers

Time-Related Burdens of Cancer Care

(2021) Arjun Gupta et al.   JCO Oncology Practice

The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells

(2020) Wen-Qi Cai et al.   Frontiers in Oncology

Colorectal adenocarcinoma‐derived EGFR mutants are oncogenic and sensitive to EGFR‐targeted monoclonal antibodies, cetuximab and panitumumab

(2019) Nayoung Kim et al.   INTERNATIONAL JOURNAL OF CANCER

A Rare EGFR–SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib

(2019) Yong Li et al.   ONCOLOGIST

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

(2018) J Remon et al.   ANNALS OF ONCOLOGY

PUMA mediates the anti-cancer effect of osimertinib in colon cancer cells

(2017) Lingchuan Guo et al.   OncoTargets and Therapy

Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants

(2015) Angela K.J. Park et al.   Oncotarget

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

(2009) Tetsuya Mitsudomi et al.   FEBS Journal